Publications
2022
Are UK pharmacists ready for consultant-level practice? A cross-sectional survey of self-assessed development needs
Forsyth, P., Radley, A., Marra, F., Roberts, D., Sehrawat, M., Aiello, M., . . . Roberts, S. (2022). Are UK pharmacists ready for consultant-level practice? A cross-sectional survey of self-assessed development needs. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE, 30(6), 559-566. doi:10.1093/ijpp/riac070
Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study
McDaniel, K., Utz, A. E., Akbashev, M., Fuller, K. G., Boyle, A., Davidson, K., . . . Miller, L. S. (2022). Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study. JOURNAL OF VIRAL HEPATITIS, 29(12), 1073-1078. doi:10.1111/jvh.13750
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. ANNALS OF INTERNAL MEDICINE, 175(5), 744-+. doi:10.7326/M22-0281
2021
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
Marra, F., Smolders, E. J., El-Sherif, O., Boyle, A., Davidson, K., Sommerville, A. J., . . . Back, D. (2021). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. DRUGS IN R&D, 21(1), 9-27. doi:10.1007/s40268-020-00333-0
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions
Back, D., Marzolini, C., Hodge, C., Marra, F., Boyle, A., Gibbons, S., . . . Khoo, S. (2021). COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(1), 212-213. doi:10.1111/bcp.14358
2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(12), 3417-3424. doi:10.1093/jac/dkaa340
POLYPHARMACY IN HCV-INFECTED PATIENTS WHO USE DRUGS TREATED WITH GLECAPREVIR/PIBRENTASVIR: A REAL-WORLD ANALYSIS FROM 9 COUNTRIES
Larrey, D., Puoti, M., Piekarska, A., Back, D., Marra, F., Bondin, M., . . . Roncero, C. (2020). POLYPHARMACY IN HCV-INFECTED PATIENTS WHO USE DRUGS TREATED WITH GLECAPREVIR/PIBRENTASVIR: A REAL-WORLD ANALYSIS FROM 9 COUNTRIES. In HEPATOLOGY Vol. 72 (pp. 567A). Retrieved from https://www.webofscience.com/
REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND SUBSTANCE ABUSE DISORDERS TREATED WITH GLECAPREVIR/PIBRENTASVIR FOR 8 WEEKS: A POOLED ANALYSIS OF MULTINATIONAL POST-MARKETING OBSERVATIONAL STUDIES
Rizzardini, G., Gschwantler, M., Bourgeois, S., Mullhaupt, B., Mazur, W., Bondin, M., . . . Foucher, J. (2020). REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND SUBSTANCE ABUSE DISORDERS TREATED WITH GLECAPREVIR/PIBRENTASVIR FOR 8 WEEKS: A POOLED ANALYSIS OF MULTINATIONAL POST-MARKETING OBSERVATIONAL STUDIES. In HEPATOLOGY Vol. 72 (pp. 568A-569A). Retrieved from https://www.webofscience.com/
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis (vol 37, pg 4033, 2020)
Lampertico, P., Mauss, S., Persico, M., Barclay, S. T., Marx, S., Lohmann, K., . . . Flamm, S. (2020). Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis (vol 37, pg 4033, 2020). ADVANCES IN THERAPY, 37(11), 4755-4756. doi:10.1007/s12325-020-01482-z
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis
Lampertico, P., Mauss, S., Persico, M., Barclay, S. T., Marx, S., Lohmann, K., . . . Flamm, S. (2020). Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis. ADVANCES IN THERAPY, 37(9), 4033-4042. doi:10.1007/s12325-020-01449-0
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis
Boyle, A., Marra, F., Peters, E., Datta, S., Ritchie, T., Priest, M., . . . Barclay, S. T. (2020). Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. JOURNAL OF VIRAL HEPATITIS, 27(4), 371-375. doi:10.1111/jvh.13239
Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy
Schulte, B., Wuebbolding, M., Marra, F., Port, K., Manns, M. P., Back, D., . . . Maasoumy, B. (2020). Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. OPEN FORUM INFECTIOUS DISEASES, 7(2). doi:10.1093/ofid/ofaa040
2019
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
Back, D., Belperio, P., Bondin, M., Negro, F., Talal, A. H., Park, C., . . . Marra, F. (2019). Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. JOURNAL OF VIRAL HEPATITIS, 26(8), 951-960. doi:10.1111/jvh.13110
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
Ferenci, P., Bourgeois, S., Buggisch, P., Norris, S., Curescu, M., Larrey, D., . . . Flisiak, R. (2019). Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. JOURNAL OF VIRAL HEPATITIS, 26(6), 685-696. doi:10.1111/jvh.13080
Drug-drug interactions in HCV therapy: Still relevant for clinical practice?
Schulte, B., Wubbolding, M., Port, K., Manns, M. P., Back, D., Marra, F., . . . zu Siederdissen, C. H. (2019). Drug-drug interactions in HCV therapy: Still relevant for clinical practice?. In JOURNAL OF HEPATOLOGY Vol. 70 (pp. E240). doi:10.1016/S0618-8278(19)30453-0
Drug Interactions in the Treatment of Hepatitis C Virus Infection - still relevant for clinical Practice?
Schulte, B., Wuebbolding, M., Port, K., Back, D., Marra, F., Manns, M. P., . . . zu Siederdissen, C. H. (2019). Drug Interactions in the Treatment of Hepatitis C Virus Infection - still relevant for clinical Practice?. In INTERNIST Vol. 60 (pp. S27). Retrieved from https://www.webofscience.com/
EFFICACY OF 8 WEEKS GLECAPREVIR/PIBRENTASVIR IN ROUTINE CARE OF PATIENTS WITH CIRRHOSIS AND NON GENOTYPE 3 INFECTION.
Marra, F., Boyle, A., Peters, E., Morris, J., Priest, M., Mcdonald, N., & Barclay, S. T. (2019). EFFICACY OF 8 WEEKS GLECAPREVIR/PIBRENTASVIR IN ROUTINE CARE OF PATIENTS WITH CIRRHOSIS AND NON GENOTYPE 3 INFECTION.. In HEPATOLOGY Vol. 70 (pp. 957A-958A). Retrieved from https://www.webofscience.com/
GLECAPREVIR/PIBRENTASVIR FOR PATIENTS WITH MARKERS OF ADVANCED CIRRHOSIS: OUTCOMES FROM ROUTINE CLINICAL CARE.
Boyle, A., Marra, F., Peters, E., Priest, M., Mcdonald, N., Datta, S., & Barclay, S. T. (2019). GLECAPREVIR/PIBRENTASVIR FOR PATIENTS WITH MARKERS OF ADVANCED CIRRHOSIS: OUTCOMES FROM ROUTINE CLINICAL CARE.. In HEPATOLOGY Vol. 70 (pp. 937A). Retrieved from https://www.webofscience.com/
USING POINT OF CARE TESTING, SIMPLIFIED ASSESSMENT AND MONITORING AND MULTIDISCIPLINARY INITIATION OF TREATMENT TO ELIMINATE HEPATITIS C IN A COMMUNITY ADDICTIONS CLINIC: RESULTS FROM PHASE 1 OF THE SPRINGBURN MICROELIMINATION PROJECT
Marra, F., Boyle, A., Govender, C., Biggart, L., Sills, L., Ritchie, T., & Barclay, S. T. (2019). USING POINT OF CARE TESTING, SIMPLIFIED ASSESSMENT AND MONITORING AND MULTIDISCIPLINARY INITIATION OF TREATMENT TO ELIMINATE HEPATITIS C IN A COMMUNITY ADDICTIONS CLINIC: RESULTS FROM PHASE 1 OF THE SPRINGBURN MICROELIMINATION PROJECT. In HEPATOLOGY Vol. 70 (pp. 963A). Retrieved from https://www.webofscience.com/
2018
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
Marra, F., zu Siederdissen, C. H., Khoo, S., Back, D., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Cornberg, M. (2018). Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(5), 961-971. doi:10.1111/bcp.13519
8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort
Boyle, A., Marra, F., Peters, E., Heydtmann, M., Cairns, H., Datta, S., & Barclay, S. (2018). 8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort. In JOURNAL OF HEPATOLOGY Vol. 68 (pp. S20). doi:10.1016/S0168-8278(18)30259-9
Grazoprevir/elbasvir dosing according to viral load and NS5A resistance: real world confirmation of the efficacy of EASL guidance
Marra, F., Boyle, A., Gunson, R., Bradley, A., Thomson, E., & Barclay, S. (2018). Grazoprevir/elbasvir dosing according to viral load and NS5A resistance: real world confirmation of the efficacy of EASL guidance. In JOURNAL OF HEPATOLOGY Vol. 68 (pp. S287-S288). doi:10.1016/S0168-8278(18)30794-3
Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders
Back, D., Belperio, P., Bondin, M., Negro, F., Talal, A., Park, C., . . . Marra, F. (2018). Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders. In JOURNAL OF HEPATOLOGY Vol. 68 (pp. S280-S281). doi:10.1016/S0168-8278(18)30778-5
Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes
Boyle, A., Marra, F., Reilly, E., Fleming, C., Heydtmann, M., Fox, R., . . . Barclay, S. (2018). Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes. In JOURNAL OF HEPATOLOGY Vol. 68 (pp. S256-S257). doi:10.1016/S0168-8278(18)30726-8
Drug-Drug Interaction Potential of Glecaprevir/Pibrentasvir Based on Real-World Use of Co-Medications in Patients with Chronic Hepatitis C Virus Infection: Data from the German Hepatitis C Registry (DHC-R)
Vermehren, J., Boeker, K. H. W., Bondin, M. I., Mauss, S., Pathil, A., Klinker, H., . . . Buggisch, P. (2018). Drug-Drug Interaction Potential of Glecaprevir/Pibrentasvir Based on Real-World Use of Co-Medications in Patients with Chronic Hepatitis C Virus Infection: Data from the German Hepatitis C Registry (DHC-R). In HEPATOLOGY Vol. 68 (pp. 409A-410A). Retrieved from https://www.webofscience.com/
2017
Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Clinical Practice: Real-World Evidence From a Multicountry Postmarketing Observational Study
Bourgeois, S., Curescu, M. G., Larrey, D. G., Marra, F., Dorr, P., Charafeddine, M., . . . Back, D. J. (2017). Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Clinical Practice: Real-World Evidence From a Multicountry Postmarketing Observational Study. In HEPATOLOGY Vol. 66 (pp. 852A). Retrieved from https://www.webofscience.com/
Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies
Marra, F., Siederdissen, C. H. Z., Khoo, S., Cornberg, M., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Back, D. (2017). Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S314). Retrieved from https://www.webofscience.com/
Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone
Boyle, A., Marra, F., Fox, R., Morris, J., Fleming, C., Reilly, E., . . . Barclay, S. T. (2017). Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S282). doi:10.1016/S0168-8278(17)30881-4
Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice
Marra, F., Boyle, A., Fox, R., Fleming, C., Reilly, E., Heydtmann, M., . . . Barclay, S. T. (2017). Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S314-S315). Retrieved from https://www.webofscience.com/
2016
Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort
Siederdissen, C. H. Z., Maasoumy, B., Marra, F., Deterding, K., Port, K., Manns, M. P., . . . Wedemeyer, H. (2016). Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. CLINICAL INFECTIOUS DISEASES, 62(5), 561-567. doi:10.1093/cid/civ973
2015
Drug-drug interactions with novel all oral interferon free antiviral agents - all issues solved?
Maasoumy, B., Siederdissen, C. H. Z., Marra, F., Deterding, K., Port, K., Manns, M. P., . . . Wedemeyer, H. (2015). Drug-drug interactions with novel all oral interferon free antiviral agents - all issues solved?. In JOURNAL OF VIRAL HEPATITIS Vol. 22 (pp. 89-90). doi:10.1111/jvh.129_12425
CLINICAL SIGNIFICANCE OF DRUG-DRUG INTERACTIONS DURING THERAPY WITH NOVEL DAAS AGAINST HCV
Siederdissen, C. H. Z., Maasoumy, B., Marra, F., Deterding, K., Port, K., Manns, M. P., . . . Wedemeyer, H. (2015). CLINICAL SIGNIFICANCE OF DRUG-DRUG INTERACTIONS DURING THERAPY WITH NOVEL DAAS AGAINST HCV. In JOURNAL OF HEPATOLOGY Vol. 62 (pp. S612). Retrieved from https://www.webofscience.com/
Co-morbidities and co-medications of patients with chronic hepatitis C (CHC) under specialist care in the UK - Challenges for scaling up HCV treatment?
Hudson, B. E., Irving, W., Barclay, S. T., Marra, F., & Walker, A. J. (2015). Co-morbidities and co-medications of patients with chronic hepatitis C (CHC) under specialist care in the UK - Challenges for scaling up HCV treatment?. In HEPATOLOGY Vol. 62 (pp. 772A). Retrieved from https://www.webofscience.com/
High prevalence of co-morbidities and complex polypharmacy with drug-drug interaction (DDI) potential in patients with chronic Hepatitis C (CHC). Consistent findings from large primary care databases in the United Kingdom, Germany, and France
Marra, F., Leber, W., Barclay, S. T., Christensen, S., Ouzan, D., Oules, V., . . . Ansolabehere, X. (2015). High prevalence of co-morbidities and complex polypharmacy with drug-drug interaction (DDI) potential in patients with chronic Hepatitis C (CHC). Consistent findings from large primary care databases in the United Kingdom, Germany, and France. In HEPATOLOGY Vol. 62 (pp. 725A). Retrieved from https://www.webofscience.com/
Prevalence of drug-drug interactions with modern interferon free antiviral regimens against hepatitis C in a large real-world cohort
Maasoumy, B., Siederdissen, C. H. Z., Marra, F., Port, K., Deterding, K., Manns, M. P., . . . Wedemeyer, H. (2015). Prevalence of drug-drug interactions with modern interferon free antiviral regimens against hepatitis C in a large real-world cohort. In HEPATOLOGY Vol. 62 (pp. 767A-768A). Retrieved from https://www.webofscience.com/